Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor
cells and slow the growth of the tumor.
PURPOSE: Phase II trial to determine the effectiveness of erlotinib in treating patients who
have locally advanced and/or metastatic endometrial cancer.